NeurogesX, Inc.
2215 Bridgepointe Parkway
Suite 200
San Mateo,
CA 94404
United States - Map
Phone: 650-358-3300
Fax: 650-649-1798
Web Site: http://www.neurogesx.com
| NeurogesX, Inc., a development stage biopharmaceutical company, focuses on developing and commercializing novel pain management therapies. The companys lead product candidate Qutenza, a dermal patch containing synthetic capsaicin, completed its phase III clinical trials to manage pain associated with peripheral neuropathic pain conditions; completed two phase III trials for HIV-distal sensory polyneuropathy; and is in the U.S. open label phase II data for painful diabetic neuropathy. Its product candidates in pipeline include NGX-1998, a non-patch liquid formulation of capsaicin for potential use in neuropathic pain conditions; NGX-1576, NGX-9674, and NGX-5752 prodrugs of acetaminophen for potential use in acute pain, including traumatic pain, post-surgical pain, and fever; and NGX-6052, an opioid prodrug for potential use in chronic pain indications. The company was formerly known as Advanced Analgesics, Inc. and changed its name to NeurogesX, Inc. in September 2000. NeurogesX, Inc. was founded in 1998 and is headquartered in San Mateo, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Anthony A. DiTonno , 60
Chief Exec. Officer, Pres and Exec. Director |
$
367.00K |
$
20.00K | Mr. Stephen F. Ghiglieri , 43
Chief Financial Officer, Principal Accounting Exec. and Sec. |
$
313.00K |
$
15.00K | Dr. Jeffrey K. Tobias MD, FCCP, 54
Chief Medical Officer |
$
353.00K | N/A | Mr. Michael E. Markels , 43
VP of Commercial Operations & Bus. Devel. |
$
262.00K | N/A | Ms. Susan P. Rinne , 57
VP of Regulatory Affairs |
$
262.00K | N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.27% Nasdaq 
0.28%
Profile
